Telemedicine has become a central access channel for medical cannabis in Germany and across Europe. In particular, digital prescription platforms enable patients to obtain cannabis prescriptions through online consultations, often involving app-based services, cross-border physician networks, and increasingly AI-supported tools. While these models offer efficiency and accessibility, they also raise complex legal and regulatory questions for platform operators, prescribing physicians, cannabis companies, and investors.
The whitepaper “Telemedicine – 20 Questions and Answers on Regulatory Affairs & Medical Law, Drug Advertising Law & Liability, Data Protection & AI” of German law firm SKW Schwarz addresses the legal framework governing telemedicine with a focus on issues that are highly relevant for cannabis prescription platforms.
Who May Prescribe Cannabis Through Digital Platforms
It begins with fundamental questions of medical and professional law: Which physicians are permitted to provide telemedical treatment in Germany? Under what conditions may foreign physicians participate in prescription platforms treating patients located in Germany? Where are the legal limits of telemedicine, and when is face-to-face treatment still required—particularly in the context of prescribing medical cannabis?
Reimbursement Rules and Prescribing Oversight
Prescription platforms are subject to heightened scrutiny when it comes to prescribing practices and reimbursement. The whitepaper examines when medicinal products may be prescribed following a purely telemedical consultation and under what circumstances statutory health insurance funds may cover telemedical cannabis treatments.
Advertising and Promotion Under German Drug Law
Advertising and marketing present particular challenges for cannabis prescription platforms. The whitepaper analyzes where and how telemedicine services may be advertised, which additional restrictions apply when treatment concepts include the prescription of medicinal products, and how the German Drug Advertising Act (HWG) restricts advertising claims. It also addresses influencer marketing, social media campaigns, and the permissibility of incentives such as discounts, vouchers, or other benefits.
Liability Risks for Physicians and Platform Operators
Liability risks are closely tied to platform-based treatment models. The whitepaper explains how liability is allocated between prescribing physicians and platform operators and how responsibility may shift when treatment is structured and delivered through digital prescription platforms.
Data Protection and Medical Confidentiality Obligations
Data protection and confidentiality are indispensable in telemedical cannabis care. The whitepaper discusses patient consent requirements, the protection of medical confidentiality under Section 203 of the German Criminal Code when prescription platforms and IT service providers are involved, and applicable data security standards, including the need for data protection impact assessments.
Artificial Intelligence and the Reach of the EU AI Act
Finally, the whitepaper turns to one of the most dynamic areas affecting prescription platforms: the use of artificial intelligence in telemedicine. It explores how the EU AI Act will influence AI-supported prescription and triage systems, whether such systems qualify as “high-risk”, and which compliance, transparency, and human-oversight obligations must be implemented.
By structuring these issues into 20 practical questions and answers, the whitepaper provides essential guidance for anyone operating or investing in telemedical cannabis prescription platforms.
Read the full whitepaper to gain clarity, reduce regulatory risk, and future-proof your telemedicine strategy.
